Long-term foscarnet therapy not associated with the development of foscarnet-resistant human immunodeficiency virus type 1 in an acquired immunodeficiency syndrome patient

✍ Scribed by Gilda Tachedjian; Jenny Hoy; Kate McGavin; Chris Birch

• Publisher: John Wiley and Sons
• Year: 1994
• Tongue: English
• Weight: 496 KB
• Volume: 42
• Category: Article
• ISSN: 0146-6615
• DOI: 10.1002/jmv.1890420220

✦ Synopsis

Sequential human-immunodeficiency virus type 1 (HIV-1) isolates from an acquired immunodeficiency syndrome (AIDS) patient on long-term foscarnet and zidovudine therapy were examined for the emergence of foscarnet resistance. One isolate obtained before therapy, and three postfoscarnet therapy HIV isolates had similar foscarnet sensitivity profiles, despite the emergence of foscarnet-resistant herpes simplex virus type 2 (HSV-2) during the period of therapy. Virion reverse transcriptases from these isolates were also equally inhibited by foscarnet. In contrast, sequential HIV isolates taken pre-and postzidovudine therapy showed a gradual increase i n I C, , to this drug. In this patient, long-term foscarnet and zidovudine therapy selected foscarnetresistant HSV and zidovudine-resistant HIV; in contrast, HIV remained susceptible to foscarnet. Concurrent administration of other anti-HIV drugs (zidovudine and interferon-a) may have hindered the development of foscarnet resistant HIV-1 in vivo.